Profile
Sector:
HealthcareCountry:
United StatesIPO:
28 September 2007Website:
http://www.harrowinc.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 19:55:13 GMTDividend
Analysts recommendations
Institutional Ownership
HROW Latest News
Harrow (HROW) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Harrow, Inc. (NASDAQ:HROW) Q1 2024 Earnings Call Transcript on May 14, 2024 at 8:00 AM ET with Company Representatives Jamie Webb, Mark L. Baum, and Andrew Boll. Conference Call Participants include Jeffrey Cohen, Chase Knickerbocker, and Brooks O'Neil. Welcome to the Harrow, Inc. First Quarter 2024 Earnings Conference Call.
Harrow, Inc. stocks have decreased by 45% since the spring of 2023, but the introduction of Iheezo and Vevye indicates a possible recovery. Iheezo, an eye numbing agent, has a large market potential and is projected to generate substantial profits for Harrow. Vevye, a treatment for dry eyes, also has a considerable market opportunity and has shown positive results since its launch.
Harrow (NASDAQ: HROW ) stock is moving on Wednesday following the release of the eyecare pharmaceutical company's earnings report for Q4 2023. The Harrow report starts with core earnings per share of -20 cents.
Harrow has two outstanding notes on offer that come up for maturity in 2026 and 2027. The 11.875% Senior Notes due 2027 offer a compelling 11.5% yield on cost and trade at a just under 3% premium to their $25 per share liquidation value. Cash and equivalents of $65.61 million at the end of Harrow's most recent quarter have been declining, and the company is not yet GAAP profitable.
Harrow: Temporary Disruption In Stock Price Creates Excellent Opportunity
Harrow, Inc. (NASDAQ:HROW ) Q3 2023 Earnings Conference Call November 13, 2023 4:45 PM ET Corporate Participants Jamie Webb - Director-Communications & Investor Relations Mark Baum - Chief Executive Officer Andrew Boll - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Jeffrey Cohen - Ladenburg Thalmann Mayank Mamtani - B. Riley Operator Good afternoon, and welcome to Harrow's Third Quarter 2023 Earnings Conference Call.
Harrow Health has guided to at least $1 billion in revenue by 2027 based on their current portfolio of drugs. The company's deep moat and strong customer relationships make it possible for them to acquire valuable drugs and generate extraordinary returns. If Harrow Health achieves their revenue target, the stock price could reach $200 per share.
Harrow Health, Inc. (NASDAQ:HROW ) Q2 2023 Earnings Conference Call August 9, 2023 4:45 PM ET Company Participants Jamie Webb - Director-Communications & Investor Relations Mark L. Baum - Chief Executive Officer & Chairman-Board of Directors Andrew Boll - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Brooks O'Neil - Lake Street Capital Markets Mayank Mamtani - B.
Harrow Health is an eye care pharmaceuticals company. The common stock has been on fire with expectations of rapidly increasing profits. HROW has 2 baby bonds, with one looking particularly interesting given an 11.6% yield to maturity.
- 1(current)
What type of business is Harrow Health?
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
What sector is Harrow Health in?
Harrow Health is in the Healthcare sector
What industry is Harrow Health in?
Harrow Health is in the Drug Manufacturers - Specialty & Generic industry
What country is Harrow Health from?
Harrow Health is headquartered in United States
When did Harrow Health go public?
Harrow Health initial public offering (IPO) was on 28 September 2007
What is Harrow Health website?
https://www.harrowinc.com
Is Harrow Health in the S&P 500?
No, Harrow Health is not included in the S&P 500 index
Is Harrow Health in the NASDAQ 100?
No, Harrow Health is not included in the NASDAQ 100 index
Is Harrow Health in the Dow Jones?
No, Harrow Health is not included in the Dow Jones index
When does Harrow Health report earnings?
The next expected earnings date for Harrow Health is 09 August 2024